HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily

Oncology Letters

Volumn 6, Issue 6, 2013, Pages 1591-1594

  Ieni, A ^a,b   Barresi, V ^a   Giuffre G ^a   Caruso, R A ^a   Lanzafame, S ^c   Villari, L ^d   Salomone, E ^d   Roz, E ^e   Cabibi, D ^f   Franco, V ^f   Certo, G ^g   Labate, A ^g   Nagar, C ^h   Magliolo, E ^b   Broggi, B ⁱ   Fazzari, C ^j   Italia, F ^k   Tuccari, G ^a,l  

^a UNIVERSITY OF MESSINA   (Italy)

^b Pathological Anatomy Unit   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d Presidio Ospedaliero Vittorio Emanuele   (Italy)

^e Health Home Service 'La Maddalena'   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g Health Home Service 'IOMI Cappellani'   (Italy)

^h Center of Eating Disorders (CeDiAl)   (Italy)

ⁱ ASP 8   (Italy)

^j Humanitas Catania Oncology Centre   (Italy)

^k Oncopathology Laboratory   (Italy)

^l UNIVERSITY OF MESSINA   (Italy)

more..

Author keywords

Gastric adenocarcinoma; HER2 status; Sicily; Trastuzumab

Indexed keywords

ALPHA FETOPROTEIN; KI 67 ANTIGEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE OVEREXPRESSION; HER2 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA;

EID: 84886803434     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1611     Document Type: Article

References (29)

1. Ross JS and McKenna BJ: The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19: 554-568, 2001.
2. Latif Z, Watters AD, Bartlett JM, et al: Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int 89: 5-9, 2002.
3. Leyland-Jones B: Trastuzumab therapy for the metastatic patient: does the primary match? Ann Oncol 13: 993-994, 2002.
4. Oxley JD, Winkler MH, Gillatt DA and Peat DS: Her-2/neu oncogene amplification in clinically localised prostate cancer. J Clin Pathol 55: 118-120, 2002.
5. Haddad R, Colevas AD, Krane JF, et al: Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39: 724-727, 2003.
6. Latif Z, Watters AD, Dunn I, et al: HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 40: 56-63, 2004.
7. Hansel DE, Ashfaq R, Rahman A, et al: A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening and treatment. Am J Clin Pathol 123: 28-35, 2005.
8. Ugocsai K, Mándoky L, Tiszlavicz L and Molnár J: Investigation of HER2 overexpression in non-small cell lung cancer. Anticancer Res 25: 3061-3066, 2005.
9. Tapia C, Savic S, Wagner U, et al: HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 9: R31, 2007.
10. Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
11. Tanner M, Hollmén M, Junttila TT, et al: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005.
12. Hede K: Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst 101: 1306-1307, 2009.
13. Moelans CB, Milne AN, Morsink FH, et al: Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cell Oncol (Dordr) 34: 89-95, 2011.
14. Gravalos C and Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523-1529, 2008.
15. Rüschoff J, Dietel M, Baretton G, et al: HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457: 299-307, 2010.
16. Giuffrè G, Ieni A, Barresi V, et al: HER2 status in unusual histological variants of gastric adenocarcinomas. J Clin Pathol 65: 237-241, 2012.
17. Crocetti E and AIRTUM Working Group: Incidence and mortality cancer trends of the Italian Network of Cancer Registries (AIRTUM), 1998-2005. Epidemiol Prev 33 (Suppl 1): 36-37, 2009.
18. Bosman FT, Carneiro F, Hruban RH and Theise ND (eds): WHO Classification of Tumours of the Digestive System. 4th edition. IARC, Lyon, France, 2010.
19. Albarello L, Pecciarini L and Doglioni C: HER2 testing in gastric cancer. Adv Anat Pathol 18: 53-59, 2011.
20. Barros-Silva JD, Leitão D, Afonso L, et al: Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 100: 487-493, 2009.
21. Marx AH, Tharun L, Muth J, et al: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 40: 769-777, 2009.
22. Grabsch H, Sivakumar S, Gray S, et al: HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic values-conclusions from 924 cases of two independent series. Cell Oncol 32: 57-65, 2010.
23. Yan B, Yau EX, Bte Omar SS, et al: A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 63: 839-842, 2010.
24. Jørgensen JT: Targeted HER2 treatment in advanced gastric cancer. Oncology 78: 26-33, 2010.
25. Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805, 2008.
26. Yano T, Doi T, Ohtsu A, et al: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15: 65-71, 2006.
27. Kumashiro Y, Yao T, Aishima S, et al: Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype. Hum Pathol 38: 857-863, 2007.
28. Gálvez-Muñoz E, Gallego-Plazas J, Gonzalez-Orozco V, et al: Hepatoid adenocarcinoma of the stomach-a different histology for not so different gastric adenocarcinoma: a case report. Int Semin Surg Oncol 6: 13, 2009.
29. Jouret-Mourin A, Hoorens A, De Hertogh G, et al: Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of working. Acta Gastroenterol Belg 75: 9-13, 2012.